Navigation Links
CuraGen Presents Update on Clinical Development Program for,Belinostat

ng).

The Phase II portion of this trial for ovarian cancer has been initiated with 16 patients having been treated with 13 patients continuing on study and undergoing assessment to determine response to treatment. This trial utilizes a Simon Two Stage Design and is initially enrolling up to 18 patients. Two of the ongoing patients have achieved an objective response and upon confirmation the Company expects to expand the trial and enroll up to 32 patients to further define the objective response rate and tolerability of belinostat in combination with carboplatin and paclitaxel.

Furthermore, this Phase II study has been broadened to include an additional arm that will enroll up to 15 patients with transitional cell cancer of the bladder in order to evaluate the activity of belinostat in combination with carboplatin and paclitaxel in this patient population. Interim results are anticipated during the first half of 2008.

NCI P7267: Phase II trial evaluating intravenous belinostat monotherapy for micropapillary/borderline low malignant potential (LMP) ovarian carcinoma or advanced platinum resistant ovarian tumors

The Phase II trial is an open-label study evaluating belinostat as a single agent treatment for patients with either micropapillary/borderline LMP ovarian carcinoma or advanced platinum resistant ovarian tumors. The primary endpoint for the study is determination of objective response, as evaluated by RECIST and GCIG CA125 criteria. Secondary endpoints include evaluation of safety and tolerability of belinostat, stable disease rates, duration of response, progression-free survival, as well as median and overall survival. Enrollment of patients is ongoing into both arms of the trial. An objective clinical response has been recently observed in the LMP arm and is pending confirmation and review. This study is being sponsored by the National Cancer Institute (NCI) under a Clinical Trials Agreement with CuraGen, and being conducted unde
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
2. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:12/24/2014)... , December 24, 2014 ... on Global Disposable Syringe Industry of 178 ... online business intelligence library. The ... Syringe Industry is a professional and deep ...  For overview analysis, the report introduces Disposable ...
(Date:12/24/2014)... 2014   Assurex Health, a personalized medicine ... providers for behavioral health and chronic pain conditions, ... in equity financing from new and existing investors, ... and Chief Executive Officer. The financing ... Assurex Health,s GeneSight ®  products.  GeneSight,s ...
(Date:12/24/2014)... 23, 2014  The American Diabetes Association is ... for people with diabetes and that all people ... of statins, in keeping with recent changes to ... American College of Cardiology (ACC) and American Heart ... most recent changes to the Association,s annual revised ...
Breaking Medicine Technology:World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
... Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), ... associated with inflammation and autoimmune disorders, today announced Dr. ... Chief Technology Officer and Senior Vice President. ... responsibility and scientific leadership has been critical to the ...
... (Nasdaq: ARAY ), the premier radiation oncology ... present at the Oppenheimer Healthcare Conference in New York ... EST/10:00 a.m. PST.  A live webcast ... Investor Relations page of the Company,s website at ...
Cached Medicine Technology:Anthera Pharmaceuticals Promotes Dr. Debra Odink to Chief Technology Officer 2
(Date:12/26/2014)... 2014 Plugin and template developers from ... Plugin for Final Cut Pro X. , “TransPack Volume 5 ... to pull off an industry professional look” Said Christina Austin, ... on TransPack Volume 5, a new level of professionalism will ... of over 50 Final Cut Pro X transitions featuring organic ...
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a comprehensive ... and marketing of a series of induction heating equipment. ... series of induction brazing equipments . , According ... brazing refers to the joining of two or ... The manager says that there are fundamental differences in ...
(Date:12/25/2014)... December 26, 2014 The ... combines beauty, strength and durability. Today, the business ... which is valid until Jan. 30, 2015. , ... of traditional hardwood. BambooFlooringChina.com is a well-known brand ... consumers worldwide to find a reliable bamboo flooring ...
(Date:12/25/2014)... “Every three months the trends for evening dresses ... will be one of the hottest styles in the next ... the company releases 26 A-line sweetheart evening dresses, and announces ... , “We are trying our best to help a lady ... Along with affordable prices, we provide discounted delivery costs to ...
(Date:12/25/2014)... Recently, BellasDress has launched its ... dresses. BellasDress has chosen their best-selling lace wedding dresses, ... the holiday season. , Now, BellasDress.com features popular ... here at discount prices. The business hopes everyone can ... , “All our elegant products are made ...
Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2
... 30 Osteotech, Inc. (Nasdaq: OSTE ), a leader ... today that its management team is scheduled to present at the ... Millennium Broadway Hotel in New York on Wednesday, August 5, 2009 ... listen-only webcast of the presentation can be accessed by visiting the ...
... , STEWARTVILLE, Minn., July 30 Rochester Medical Corporation ... ended June 30, 2009. , , The Company reported sales ... of last year. The Company also reported net loss of $77,000 or ... or $.02 per diluted share for the same period of last year. ...
... WASHINGTON, July 30 An estimated 428,000 ... Congress passes a House health reform bill, according to ... released this week by The Heritage Foundation ... The Lewin Group , a highly respected health care ...
... expert says, might help keep elderly out of hospitals ... designed to increase muscle density in the elderly could ... suggests. , The contention stems from a study of ... about a five-year span, more than 55 percent of ...
... State Influentials Gather to Discuss the Rising Cost ... , PHILADELPHIA, July 30 Teva Pharmaceuticals USA, the ... series of roundtable discussions focused on increasing access to healthcare and ... The event was held as a part of the company,s ...
... , , WASHINGTON, July 30 ... private, employer-based coverage if Congress passes a House health reform bill, ... Choices Act of 2009 released this week by ... Heritage commissioned The Lewin Group , a ...
Cached Medicine News:Health News:Rochester Medical Reports Third Quarter Results 2Health News:Rochester Medical Reports Third Quarter Results 3Health News:Rochester Medical Reports Third Quarter Results 4Health News:Rochester Medical Reports Third Quarter Results 5Health News:Rochester Medical Reports Third Quarter Results 6Health News:Rochester Medical Reports Third Quarter Results 7Health News:Rochester Medical Reports Third Quarter Results 8Health News:Rochester Medical Reports Third Quarter Results 9Health News:Rochester Medical Reports Third Quarter Results 10Health News:Rochester Medical Reports Third Quarter Results 11Health News:Thousands of New Mexicans Could Lose Private Insurance, Study Shows 2Health News:Muscle Density Linked to Disability 2Health News:Teva's Forum Draws Key Pennsylvania Healthcare Leaders 2Health News:Millions of Virginians Could Lose Private Insurance, Study Shows 2
Microscissors : Horizontal Scissors...
Microscissors : Vertical Scissors...
Sharp tipped scissors with a curvature of 12 mm to follow the contour of the retina. For cutting in the plane parallel to the retina, cutting membranes adherent to the retinal surface and all purpose...
... The Focus Diagnostics Rickettsia Indirect ... is intended for the detection ... class antibodies to Spotted Fever ... as an in vitro aid ...
Medicine Products: